Company Monitoring Page for Eisai

latest headlines for company on cafepharma

Despite CMS snub, Eisai is 'not so nervous' about Leqembi's long-term coverage prospects: US CEO
Fierce Pharma
Tue, 03/21/23 - 09:58 pm
Tags:
Eisai, Leqembi, FDA, CMS, Alzheimer's disease
Alzheimer's Association campaigns for broader Leqembi coverage: report
Fierce Pharma
Fri, 03/17/23 - 11:43 am
Tags:
CMS, Eisai, Biogen, Leqembi, Alzheimer's disease
VA to cover Eisai's new Alzheimer's drug after declining to cover Aduhelm
Endpoints
Mon, 03/13/23 - 04:44 pm
Tags:
VHA, Eisai, Biogen, Leqembi, Aduhelm, Alzheimer's disease
Eisai projects $7B in sales by 2030 for new Alzheimer's drug
Endpoints
Sun, 03/12/23 - 09:40 pm
Tags:
Eisai, Biogen, Alzheimer's disease, Leqembi
FDA sets July decision date for full approval of Leqembi
BioSpace
Mon, 03/6/23 - 12:11 pm
Tags:
Eisai, Biogen, Alzheimer's disease, Leqembi, FDA, lecanemab
ICER dials up recommended price range for Eisai's Leqembi—but still calls for sizable discount
Fierce Pharma
Wed, 03/1/23 - 06:55 pm
Tags:
ICER, Eisai, Leqembi, drug pricing, Alzheimer's disease
Despite recent approvals, significant unmet need remains in Alzheimer’s market
Clinical Trials Arena
Wed, 03/1/23 - 10:05 am
Tags:
Alzheimer's disease, Biogen, Eisai, Lundbeck, Otsuka, Avanir Pharmaceuticals, Axesome, Aduhelm, Leqembi
Medicare maintains limits on Eisai’s new Alzheimer’s drug
BioPharma Dive
Thu, 02/23/23 - 04:27 pm
Tags:
Medicare, CMS, Eisai, Biogen, Leqembi, Alzheimer's disease
Eisai Anticipates Full Approval of Leqembi as Early as July
BioSpace
Mon, 02/20/23 - 12:44 pm
Tags:
Eisai, FDA, Alzheimer's disease, Leqembi, lecanemab
BioSpace Layoff Tracker 2023: Grifols, Frequency, Eliem and More Cut Staff
BioSpace
Thu, 02/16/23 - 11:18 am
Tags:
layoffs, Grifols, Frequency Therapeutics, Eliem Therapeutics, Aligos Therapeutics, Thermo Fisher Scientific, Magenta Therapeutics, Eisai, Amgen, Y-mAbs Therapeutics, Century Therapeutics, Elevation Oncology, Calithera Biosciences, Editas Medicine, Verily, Abzena
Eisai gives first glimpse into Alzheimer’s drug launch
BioPharma Dive
Mon, 02/6/23 - 06:21 pm
Tags:
Eisai, Alzheimer's disease, drug launches, Leqembi
With all eyes on new Alzheimer's med, Eisai lays off 91 staffers on its Fycompa team
Fierce Pharma
Fri, 02/3/23 - 11:03 am
Tags:
Eisai, Fycompa, layoffs
Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval
Motley Fool
Thu, 01/19/23 - 10:15 am
Tags:
Biogen, Eisai, Alzheimer's disease, Leqembi, lecanemab
Alzheimer’s disease trials: How does Lilly’s donanemab compare to lecanemab?
Clinical Trials Arena
Fri, 01/13/23 - 10:49 am
Tags:
clinical trials, Alzheimer's disease, Eisai, Biogen, Eli Lilly, Leqembi, lecanemab, donanemab
After FDA nod, Eisai and Biogen file lecanemab in EU
Pharmaphorum
Wed, 01/11/23 - 11:04 pm
Tags:
Eisai, Biogen, lecanemab, Europe, Alzheimer's disease
Eisai learns from Biogen’s Aduhelm disaster
EP Vantage
Mon, 01/9/23 - 10:35 am
Tags:
Eisai, Biogen, Leqembi, Aduhelm, Alzheimer's disease, drug pricing
Eisai, in pricing new Alzheimer’s drug, tries to sidestep controversy
BioPharma Dive
Sun, 01/8/23 - 10:04 pm
Tags:
Eisai, Biogen, drug pricing, Leqembi, Alzheimer's disease, lecanemab
FDA approves Alzheimer’s drug from Eisai, Biogen in closely watched decision
BioPharma Dive
Fri, 01/6/23 - 03:40 pm
Tags:
Eisai, Biogen, lecanemab, Leqembi, Alzheimer's disease, FDA
Eisai and Biogen’s latest Alzheimer’s drug needs to be cheaper than the last one, analysts say
Stat
Thu, 12/22/22 - 11:10 am
Tags:
Biogen, Eisai, Alzheimer's disease, drug pricing, ICER, lecanemab
3rd patient death potentially tied to Eisai's Alzheimer's drug reported
Fierce Biotech
Thu, 12/22/22 - 11:05 am
Tags:
Biogen, Eisai, Alzheimer's disease, clinical trials, patient deaths, lecanemab

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.